Top

Published in:

01-01-2021 | Patient Opinion

Patients’ beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch

Authors: Chiara Gasteiger, Maria Lobo, Nicola Dalbeth, Keith J. Petrie

Published in: Rheumatology International | Issue 1/2021

Abstract

Although patient acceptance is important for biosimilar adoption and reducing healthcare costs, many patients perceive biosimilars to be unsafe and have concerns about switching. Studies show that patients’ characteristics influence negative perceptions toward generic drugs, but little research has explored biosimilar acceptance. This study examines which demographic and psychological characteristics are associated with patients’ safety perceptions and concerns about switching to biosimilars. Ninety-six patients taking bio-originators for rheumatic conditions (65% for rheumatoid arthritis) completed the Brief Illness Perceptions Questionnaire, Beliefs about Medicines Questionnaire and Perceived Sensitivity to Medicines Scale. Demographic factors, information seeking, concerns about switching and safety perceptions were also assessed. Pearson’s correlations and hierarchical linear regressions were conducted to explore whether patient characteristics are associated with perceptions of biosimilars. Negative safety perceptions were associated with being female, short-term bio-originator use, illness beliefs, seeking health information online, high perceived sensitivity to medicines and negative beliefs about medicines. Only being female (β = 0.24, P = 0.02) was independently associated. More concerns about switching were associated with being female, illness beliefs, high perceived sensitivity to medicines, information-seeking behaviours and preferring innovator drugs. Seeking health information online (β = 0.20, P = 0.04), preferring innovator drugs (β = 0.29, P = 0.004) and stronger emotional responses (β = 0.26, P = 0.01) were independently associated. Perceived bio-originator effectiveness was inversely associated with preferring biosimilars (r_s= – 0.33, P < 0.001). Patients who have stronger emotional responses to their condition, are females, seek health information online and prefer innovator drugs that have more negative perceptions about biosimilars. Experiences with bio-originators influence attitudes towards switching.

Eleryan MG, Akhiyat S, Rengifo-Pardo M, Ehrlich A (2016) Biosimilars: Potential implications for clinicians. Clin Cosmet Investig Dermatol 9:135–142. https://doi.org/10.2147/CCID.S91691CrossRefPubMedPubMedCentral

Escasany AA, Cumplido DR (2015) Biosimilars: Current reality, promising future? Medicina Clínica (English Edition) 145:18–20. https://doi.org/10.1016/j.medcli.2015.03.006CrossRef

Patel D, Park KT (2017) Path of interchangeability of biosimilars in pediatric inflammatory bowel disease: Quality before cost savings. J Pediatr Gastroenterol Nutr 65:134–136. https://doi.org/10.1097/MPG.0000000000001572CrossRefPubMedPubMedCentral

Sullivan E, Piercy J, Waller J, Black CM, Kachroo S (2017) Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany. PLoS One 12:1–14. https://doi.org/10.1371/journal.pone.0175826CrossRef

Wilkins AR, Venkat MV, Brown AS, Dong JP, Ran NA, Hirsch JS, Close KL (2014) Patient perspectives on biosimilar insulin. J Diabetes Sci Technol 8:23–25. https://doi.org/10.1177/1932296813515132CrossRefPubMedPubMedCentral

Attara G, Bressler B, Bailey R, Marshall JK, Panaccione R, Aumais G (2016) Canadian patient and caregiver perspectives on subsequent entry biologics/biosimilars for inflammatory bowel disease. Gastroenterology 150:443–444. https://doi.org/10.1016/s0016-5085(16)31540-2CrossRef

Ighani A, Wang JY, Manolson MF (2018) An evaluation of psoriasis patient perceptions and understanding of biosimilars: A Canadian survey comparing biologic and nonbiologic users. J Cutan Med Surg 22:365–367. https://doi.org/10.1177/1203475417746337CrossRefPubMed

Rezk MF, Pieper B (2017) Treatment outcomes with biosimilars: Be aware of the nocebo effect. Rheumatol Ther 4:209–218. https://doi.org/10.1007/s40744-017-0085-zCrossRefPubMedPubMedCentral

Betegnie A, Gauchet A, Lehmann A, Grange L, Roustit M, Baudrant M, Bedouch P, Allenet B (2016) An assessment of patients’ adherence using a self-report questionnaire. J Rheumatol 43:724–730. https://doi.org/10.3899/jrheum.150414CrossRefPubMed

10.

Figueiras MJ, Alves NC, Marcelino D, Cortes MA, Weinman J, Horne R (2009) Assessing lay beliefs about generic medicines: Development of the generic medicines scale. Psychol Health Med 14(3):311–321. https://doi.org/10.1080/13548500802613043CrossRefPubMed

11.

MacKrill K, Petrie KJ (2018) What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey. BMJ Open 8(10):e023667. https://doi.org/10.1136/bmjopen-2018-023667CrossRefPubMedPubMedCentral

12.

Kleinstäuber M, MacKrill K, Petrie KJ (2018) Characteristics of individuals who prefer branded innovator over generic medicines: a New Zealand general population survey. Drugs Therapy Perspect 34(10):478–483. https://doi.org/10.1007/s40267-018-0541-zCrossRef

13.

Babar ZU, Kan SW, Scahill S (2014) Interventions promoting the acceptance and uptake of generic medicines: A narrative review of the literature. Health Policy 117:285–296. https://doi.org/10.1016/j.healthpol.2014.06.004CrossRefPubMed

14.

Olsson E, Svensberg K, Wallach-Kildemoes H, Carlsson E, Hällkvist C, Kaae S, Kälvemark Sporrong S (2018) Swedish patients’ trust in the bioequivalence of interchangeable generics. What factors are important for low trust? Pharm Pract. https://doi.org/10.18549/PharmPract.2018.04.1298CrossRef

15.

Alrasheedy AA, Hassali AM, Stewart K, Kong DCM, Aljadhey H, Ibrahim MIM, Al-Tamimi SK (2014) Patient knowledge, perceptions, and acceptance of generic medicines: A comprehensive review of the current literature. Patient Intell 4:1–29. https://doi.org/10.2147/PI.S46737CrossRef

16.

Faasse K, Grey A, Horne R, Petrie KJ (2015) High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information-seeking about medication. Pharmacoepidemiol Drug Saf 24:592–599. https://doi.org/10.1002/pds.3751CrossRefPubMed

17.

Pechlivanoglou P, van der Veen WJ, Bos JH, Postma MJ (2011) Analyzing generic and branded substitution patterns in the Netherlands using prescription data. BMC Health Serv Res 11:89. https://doi.org/10.1186/1472-6963-11-89CrossRefPubMedPubMedCentral

18.

Gasteiger C, Jones ASK, Kleinstäuber M, Lobo M, Horne R, Dalbeth N, Petrie KJ (2019) The effects of message framing on patients’ perceptions and willingness to change to a biosimilar in a hypothetical drug switch. Arthr Care Res. https://doi.org/10.1002/acr.24012(Epub ahead of print)CrossRef

19.

Broadbent E, Petrie KJ, Main J, Weinman J (2006) The brief illness perception questionnaire. J Psychom Res 60:631–637. https://doi.org/10.1016/j.jpsychores.2005.10.020CrossRef

20.

Broadbent E, Wilkes C, Koschwanez H, Weinman J, Norton S, Petrie KJ (2015) A systematic review and meta-analysis of the Brief Illness Perception Questionnaire. Psychol Health 30(11):1361–1385. https://doi.org/10.1080/08870446.2015.1070851CrossRefPubMed

21.

Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14:1–24. https://doi.org/10.1080/08870449908407311CrossRef

22.

Heller MK, Chapman SC, Horne R (2015) Beliefs about medication predict the misattribution of a common symptom as a medication side effect - evidence from an analogue online study. J Psychosom Res 79:519–529. https://doi.org/10.1016/j.jpsychores.2015.10.003CrossRefPubMed

23.

Bautista RE, Gonzales W, Jain D (2011) Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs. Epilepsy Res 95:158–167. https://doi.org/10.1016/j.eplepsyres.2011.03.014CrossRefPubMed

24.

Horne R, Faasse K, Cooper V, Diefenbach MA, Leventhal H, Leventhal E, Petrie KJ (2013) The perceived sensitivity to medicines (PSM) scale: An evaluation of validity and reliability. Br J Health Psychol 18:18–30. https://doi.org/10.1111/j.2044-8287.2012.02071.xCrossRefPubMed

25.

Nolke L, Mensing M, Kramer A, Hornberg C (2015) Sociodemographic and health-(care-)related characteristics of online health information seekers: a cross-sectional German study. BMC Public Health 15:31. https://doi.org/10.1186/s12889-015-1423-0CrossRefPubMedPubMedCentral

26.

Dunne S, Shannon B, Dunne C, Cullen W (2014) Patient perceptions of generic medicines: A mixed-methods study. Patient 7:177–185. https://doi.org/10.1007/s40271-013-0042-zCrossRefPubMed

27.

Shaw Y, Metes ID, Michaud K, Donohue JM, Roberts MS, Levesque MC, Chang JC (2018) Rheumatoid arthritis patients’ motivations for accepting or resisting disease-modifying antirheumatic drug treatment regimens. Arthritis Care Res 70(4):533–541. https://doi.org/10.1002/acr.23301CrossRef

28.

Graham-Engeland JE, Song S, Mathur A, Wagstaff DA, Klein LC, Whetzel C, Ayoub WT (2019) Emotional state can affect inflammatory responses to pain among rheumatoid arthritis patients: preliminary findings. Psychol Rep 122(6):2026–2049. https://doi.org/10.1177/0033294118796655CrossRefPubMed

29.

Dures E, Fraser I, Almeida C, Peterson A, Caesley J, Pollock J, Ambler N, Morris M, Hewlett S (2017) Patients' perspectives on the psychological impact of inflammatory arthritis and meeting the associated support needs: open-ended responses in a multi-centre survey. Musculoskeletal Care 15(3):175–185. https://doi.org/10.1002/msc.1159CrossRefPubMed

30.

McMullan RD, Berle D, Arnáez S, Starcevic V (2019) The relationships between health anxiety, online health information seeking, and cyberchondria: Systematic review and meta-analysis. J Affective Disord 245:270–278. https://doi.org/10.1016/j.jad.2018.11.037CrossRef

31.

Gasteiger N, Grainger RKD (2018) Arthritis-Related Support in a Social Media Group for Quilting Hobbyists: Qualitative Study. Interact J Med Res 7(2):e11026. https://doi.org/10.2196/11026CrossRefPubMedPubMedCentral

32.

Teeple A, Ginsburg S, Howard L, Huff L, Reynolds C, Walls D, Ellis LA, Curtis JR (2019) Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin 35(4):603–609. https://doi.org/10.1080/03007995.2018.1560221CrossRefPubMed

33.

Edwards CJ, Hercogova J, Albrand H, Amiot A (2019) Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther 19(10):1001–1014. https://doi.org/10.1080/14712598.2019.1610381CrossRefPubMed

34.

Rathe J, Larsen P, Andersen M, Paulsen M, Jarbol D, Thomsen J, Soendergaard J (2013) Associations between generic substitution and patients' attitudes, beliefs and experiences. Eur J Clin Pharmacol 69(10):1827–1836. https://doi.org/10.1007/s00228-013-1539-zCrossRefPubMed

35.

Dunne S (2016) What do users of generic medicines think of them? A systematic review of consumers' and patients' perceptions of, and experiences with, generic medicines. Patient 9:499–510. https://doi.org/10.1007/s40271-016-0176-xCrossRefPubMed

36.

Dunne S, Shannon B, Hannigan A, Dunne C, Cullen W (2014) Physician and pharmacist perceptions of generic medicines: What they think and how they differ. Health Policy 116:214–223. https://doi.org/10.1016/j.healthpol.2014.03.007CrossRefPubMed

37.

Haghnejad V, Le Berre C, Dominique Y, Zallot C, Guillemin F, Peyrin-Biroulet L (2019) Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Dig Liver Dis. https://doi.org/10.1016/j.dld.2019.09.012CrossRefPubMed

38.

Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG (2016) Patient attitudes and understanding about biosimilars: An international cross-sectional survey. Patient Prefer Adher 10:937–948. https://doi.org/10.2147/PPA.S104891CrossRef

39.

van Overbeeke E, De Beleyr B, de Hoon J, Westhovens R, Huys I (2017) Perception of originator biologics and biosimilars: A survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs 31:447–459. https://doi.org/10.1007/s40259-017-0244-3CrossRefPubMed

Title: Patients’ beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch
Authors: Chiara Gasteiger
Maria Lobo
Nicola Dalbeth
Keith J. Petrie
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 1/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04576-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Think twice before submitting your precious articles for publication!

Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data

Protracted febrile myalgia syndrome as the first manifestation of familial Mediterranean fever in children: case-based review

Response to ‘How to define disease severity accurately in patients with familial Mediterranean fever’

Altered expression of apoptosis-related, circulating cell-free miRNAs in children with familial Mediterranean fever: a cross-sectional study

Performance of the new Eurofever/PRINTO classification criteria in Familial Mediterranean fever patients with a single exon 10 mutation in childhood

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials